Clinical trials: MAFLD in Prediabetes and Diabetes
MAFLD in Prediabetes and Diabetes
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
Metabolic-dysfunction-associated fatty liver disease (MAFLD) has evolved as a major health problem recently. Discovering ways to prevent or delay the progression of MAFLD has become a global focus.
- Trial name
- SGLT2 (NCT07891234)
- Testing
- Dapagliflozin 5Mg Tab, Metfomin 500 mg, Dapagliflozin (10mg Tab)
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Sherihan AboElyazed Mohamed Khalil